What is Sano Genetics?
Sano Genetics operates as a sophisticated digital platform designed to accelerate research in personalized medicine. Founded by a team of Ph.D. researchers from the University of Cambridge, the platform empowers individuals to contribute their genetic and medical data to high-impact clinical trials and research studies. By prioritizing user privacy and data sovereignty, Sano Genetics creates a unique ecosystem where patients become active participants in the drug discovery process. This model not only streamlines the recruitment process for pharmaceutical companies but also ensures that research is grounded in diverse, real-world genetic insights, positioning the firm as a critical infrastructure provider in the global biotech landscape.
How much funding has Sano Genetics raised?
Sano Genetics has raised a total of $25.8M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$11M
Other Financing Round
$11.4M
Angel/Seed (2021): $3.4M with participation from Seedcamp Ltd, January Ventures, Cambridge Enterprise, and Episode 1 Ventures LLP
Series A (2022): $11M led by MMC Ventures
Other Financing Round (2024): $11.4M supported by Plural
Key Investors in Sano Genetics
Plural
Plural is a strategy consultancy helping businesses to deliver transformational growth, advising major corporates and private equity investors across the media, technology, and industrial sectors.
MMC Ventures
MMC Ventures is a venture capital firm that scales technology companies by providing deep operational expertise and backing transformative business models from the early stages.
Episode 1 Ventures LLP
Episode 1 Ventures is a London-based venture capital firm specializing in early-stage software-driven businesses with high growth potential and a focus on market disruption.
What's next for Sano Genetics?
With the recent infusion of capital, Sano Genetics is well-positioned to scale its operations and expand its reach within the global clinical research market. The company is expected to focus on enhancing its data-matching algorithms and strengthening its partnerships with major pharmaceutical entities. As the industry shifts toward more personalized therapeutic approaches, Sano Genetics' ability to provide high-quality, consented data will be a key differentiator. Future strategic initiatives will likely involve deepening its technological moat, expanding its user base, and potentially entering new international markets to further solidify its leadership in the personalized medicine data space.
See full Sano Genetics company page
